NCT01329276View on ClinicalTrials.gov

Assess Particle Deposition and Acute Effects of Symbicort® Forte Turbohaler®) in COPD Patients.

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

January 31, 2011

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Symbicort® forte Turbohaler®

320 µg budesonide / 9 µg formoterol fumarate dihydrate

Trial Locations (1)

2650

University Hospital Antwerp, Edegem (Antwerp)

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University Hospital, Antwerp

OTHER

NCT01329276 - Assess Particle Deposition and Acute Effects of Symbicort® Forte Turbohaler®) in COPD Patients. | Biotech Hunter | Biotech Hunter